ADT Use Not Linked to Dementia Risk in Study of Prostate Cancer Patients

ADT Use Not Linked to Dementia Risk in Study of Prostate Cancer Patients
The use of androgen deprivation therapy (ADT) in patients with prostate cancer is not associated with an increased risk of dementia, according to a recent study in the Journal of Clinical Oncology. The study, “Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer,” took issue with findings in three prior observational studies reporting a link between ADT and an increased risk of dementia and Alzheimer's disease. The researchers also noted these earlier studies had "conflicting findings." Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. For this reason, androgen deprivation therapies, which reduce the levels of androgen hormones or their ability to bind to their specific receptors, are a mainstay treatment of patients with advanced prostate cancer and are increasingly being used in patients with localized disease. Although ADT has been shown to delay prostate cancer progression, this therapy has also been linked with several adverse events, including diabetes, cardiovascular disease, and, possibly, cognitive impairment. But many men with prostate cancer represent an older population, people already thought to be at an increased risk of cognitive impairment and dementia. So it is important to assess whether ADT use itself may cause increased incidence of dementia. Researchers, led by Farzin Khosrow-Khavar, PhD
Subscribe or to access all post and page content.